Merck | Home
At Merck, we're following the science to tackle some of the world's greatest health threats. Get a glimpse of how we work to improve lives.
Discover Job Opportunities at Merck | Merck Careers
Explore current job opportunities at Merck. Learn more about careers in Business Support, Clinical, Engineering, Information Technology, Research & Development, Manufacturing and Marketing.
Products list - Merck.com
For information about Merck’s products and services including the reporting of an Adverse Event or Product Quality Complaint with a specific Merck product, please call the Merck National Service Center.
Who we are - Merck.com
We aspire to be the premier research-intensive biopharmaceutical company. We’re at the forefront of research to deliver innovative health solutions that advance the prevention and treatment of diseases in people and animals.
Work with us in Durham, New Carolina | Merck Careers
Discover Merck Manufacturing & Supply jobs in Durham, North Carolina. Apply today!
Merck Provides Update on Phase 3 KEYNOTE-867 and KEYNOTE …
2024年8月29日 · Merck is discontinuing the Phase 3 KEYNOTE-867 trial evaluating KEYTRUDA ® (pembrolizumab), Merck’s anti-PD-1 therapy, in combination with stereotactic body radiotherapy (SBRT) for the treatment of patients with stage I or II (stage IIB N0, M0) non-small cell lung cancer (NSCLC), including those who are medically inoperable or have refused ...
Investor relations - Merck.com
2024年10月19日 · Merck’s (NYSE: MRK) Q1 2024 results reflect continued strong growth in oncology and vaccines. Our company announced Q1 worldwide sales of $15.8 billion, an increase of 9% from Q1 2023. “Merck has begun 2024 with continuing momentum in our business.
Contact us - Merck.com
Merck's U.S. headquarters, worldwide office, adverse event, investors, media, supplies and animal health contact information.
Merck Announces Phase 3 Trial Initiation for Bomedemstat, an ...
2024年8月27日 · Merck Announces Phase 3 Trial Initiation for Bomedemstat, an Investigational Candidate for the Treatment of Certain Patients With Essential Thrombocythemia. The initiation of a second Phase 3 clinical trial for bomedemstat demonstrates company’s commitment to advancing research in myeloproliferative neoplasms (MPNs) RAHWAY, N.J.-- (BUSINESS ...
Research - Merck.com
We’re calling all aspiring world-class scientists who want to be a part of cutting-edge work to save and improve lives. Explore the possibilities. At Merck, we follow the science. Learn about Merck's research and products by getting to know the science, strategy and brains behind the innovations.